Biohaven's spinal muscular atrophy drug fails to meet main goal in study
Portfolio Pulse from
Biohaven's experimental drug for spinal muscular atrophy showed improvement in motor function but did not achieve statistical significance in a late-stage study.
November 25, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biohaven's drug for spinal muscular atrophy improved motor function but failed to meet the main goal of statistical significance in a late-stage study.
The failure to achieve statistical significance in a late-stage study is a setback for Biohaven's drug development, likely leading to negative investor sentiment and a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100